Actualités et vidéos - HYTN INNOVATIONS MMOED - Anglais

VANCOUVER, British Columbia, Dec. 16, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) ("HYTN" or "the Company"), a pharmaceutical company specializing in the development, formulation, and manufacturing of psychoactive and psychotropic compounds, including cannabis and psilocybin, is pleased to announce its successful export of cannabis to the United Kingdom’s 4C LABS. This announcement follows the news from November 28, 2024, that the Company received its...

VANCOUVER, British Columbia, Nov. 28, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or “the Company”), a pharmaceutical company specializing in the development, formulation, and manufacturing of psychoactive and psychotropic compounds, including cannabis and psilocybin, is pleased to announce the receipt of initial orders and import permits from the UK's 4C Labs, marking a significant milestone in their partnership. This achievement allows...

VANCOUVER, British Columbia, Nov. 08, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or “the Company”), a company specializing in the pharmaceutical development and production of psychoactive and psychotropic compounds, including cannabis and psilocybin, is pleased to announce that it has engaged bullVestor Medien GmbH (“bullVestor”) (address: Gutenhofen 4, 4300, St. Valentin, Austria email: [email protected] ) to provide marketing...

VANCOUVER, British Columbia, Oct. 09, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN , FSE: 85W0 , OTC PINK: HYTNF ) (“ HYTN ” or “the Company ”), a pharmaceutical company specializing in the development, formulation, and manufacturing of psychoactive and psychotropic compounds, including cannabis and psilocybin, proudly announces that it has received an additional Good Manufacturing Practices (“GMP”) certification for its Kelowna manufacturing facility. This certification...

VANCOUVER, British Columbia, Sept. 27, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or “the Company”), a pharmaceutical company specializing in the development, formulation, and manufacturing of psychoactive and psychotropic compounds, including cannabinoids and psilocybin, is pleased to announce, further to its news release dated July 19, 2024, that it has filed a Business Acquisition Report (BAR) in respect of its acquisition of Prism...

VANCOUVER, British Columbia, Sept. 10, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or “the Company”), a pharmaceutical company specializing in the development, formulation, and manufacturing of psychoactive and psychotropic compounds, including cannabinoids and psilocybin, is proud to announce the establishment of international manufacturing and pricing agreements (the Agreements) with 4C LABS, a leading importer and distributor of...

VANCOUVER, British Columbia, July 29, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN | FSE: 85W0 | OTC PINK: HYTNF) “HYTN” or “the Company”, a pharmaceutical company specializing in the development, formulation, and manufacturing of products containing psychoactive and psychotropic compounds, including cannabis and psilocybin, is pleased to announce its approval for trading on the OTC PINK Market ("OTC PINK") effective July 29th, 2024, under the trading symbol “HYTNF”....

VANCOUVER, British Columbia, July 19, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN | FSE: 85W0) "HYTN" or "The Company", a leader in the development, formulation, and manufacturing of psychoactive and psychotropic compounds, including cannabis and psilocybin, is pleased to announce, further to its news release dated June 13, 2024, the completion of its acquisition (“ Acquisition ”) of all of the issued and outstanding share capital of Prism Scientific Labs Inc. (Prism), a...

VANCOUVER, British Columbia, June 27, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN | FSE: 85W0) “HYTN” or “The Company”, a leader in the development, formulation, and manufacturing of products containing psychoactive and psychotropic compounds, including cannabis and psilocybin, is pleased to announce that it has been granted a Drug Establishment License (DEL) by Health Canada. This license allows HYTN to engage in the GMP fabrication, packaging, and labeling of non-sterile...

VANCOUVER, British Columbia, May 01, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN “HYTN” or “The Company”), a leader in the development, formulation, and manufacturing of products containing psychoactive and psychotropic compounds including cannabis, applauds the recent formal recommendation by the U.S. Justice Department, endorsed by the Drug Enforcement Agency (DEA), to reclassify cannabis from a Schedule I to a Schedule III controlled substance. This historic shift,...

VANCOUVER, British Columbia, April 22, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN | FSE: 85W0) “HYTN” or “The Company”, a leader in the development, formulation, and manufacturing of products containing psychoactive and psychotropic compounds, including cannabis, is pleased to announce significant advancements in its Good Manufacturing Practice (GMP) stability programs. Stability programs constitute a cornerstone of all GMP guidelines and are vital for achieving GMP...

VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN, “HYTN” or “The Company”), a leader in the development, formulation, and manufacturing of products containing psychoactive and psychotropic compounds, including cannabis, welcomed Health Canada’s conduct of a Drug Establishment License (DEL) audit. The audit, which aims to expand the Company's Good Manufacturing Practices (GMP) capabilities, follows the recent achievement of GMP...

VANCOUVER, British Columbia, April 03, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN | FSE: 85W0, "HYTN" or "The Company"), a leader in the development, formulation, and manufacturing of products containing psychoactive and psychotropic compounds, including cannabis, is pleased to provide an update on the company’s new strategic goals and plans for global commercialization. This follows the recent achievement of Good Manufacturing Practices (GMP) certification for HYTN's Kelowna...

VANCOUVER, British Columbia, March 21, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN "HYTN or The Company"), a Canadian company at the forefront of developing, formulating, and manufacturing products with psychoactive and psychotropic compounds, including those from cannabis and psilocybin, has been awarded Good Manufacturing Practice (GMP) certification by Australia's Therapeutic Goods Administration (TGA) for its Kelowna production facility. This announcement supplements the...

VANCOUVER, British Columbia, March 04, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN | FSE: 85W0) (the “ Company ” or “ HYTN ”), a company at the forefront of developing, formulating, and manufacturing products with psychoactive and psychotropic compounds, including those from cannabis and psilocybin, proudly announces the successful completion of a Good Manufacturing Practices (“ GMP ”) audit by Australia's Therapeutic Goods Administration (“ TGA ”) at their Kelowna...

VANCOUVER, British Columbia, Feb. 20, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN " HYTN or The Company "), a leader in the cannabis sector known for specialized psychoactive and psychotropic product development, is excited to announce the expansion of its 100 mg Nano Shot Citrus (“ Nano Shot ”) to the key markets of British Columbia and Alberta. Following its initial success in Ontario, Canada's largest market, this move represents a significant stride in the company's...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Feb. 09, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (the “ Company ” or “ HYTN ”) (CSE: HYTN) is pleased to announce a non-brokered private placement of up to 13,333,334 units of the Company (“ Units ”) at a price of $0.075 per Unit (the “ Offering ”), for aggregate gross proceeds of up to $1,000,000.05. Each Unit will be composed of one (1) common...

VANCOUVER, British Columbia, Oct. 26, 2023 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (the “ Company ” or “ HYTN ”) (CSE: HYTN) is pleased to announce that it has closed its previously announced non-brokered private placement of units of the Company (“ Units ”) by issuing a total of 5,050,000 Units at a price of $0.10 per Unit (the “ Offering ”) for aggregate gross proceeds of $505,000. Each Unit consists of one (1) common share in the capital of the Company (a “ Share ”) and...

VANCOUVER, British Columbia, March 02, 2023 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (“ HYTN ” or the “ Company ”) (CSE: HYTN), a Vancouver-based company specializing in the production of psychoactive and psychotropic compounds, announced today that it has submitted an amendment to its Controlled Drugs and Substances Dealers License with Health Canada. The amendment, if approved, will allow the company to expand its work to include additional compounds such as MDMA, ketamine, LSD,...

VANCOUVER, British Columbia, Feb. 23, 2023 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (“ HYTN ” or the “ Company ”) (CSE: HYTN) announced that it has successfully initiated cultivation of psilocybin mushrooms under its Dealer’s License granted by Health Canada in accordance with the Controlled Drugs and Substances Act. This announcement is a significant development supporting HYTN's mission to be a leading manufacturer of psychoactive and psychotropic compounds. The company also...